Benutzerspezifische Werkzeuge


  1. Haller, H.; Leonhardt, W.; Hanefeld, M.; Julius, U.;
    Relationship between Adipocyte Hypertrophy and Metabolic Disturbances
    Endokrinologie 74 (1979) 63-72
  2. Julius, U.; Leonhardt, W.; Schulze, J.; Hanefeld, M.; Haller, H.;
    Messung des Triglycerid-Turnovers bei Normo- und Hypertriglyceridämie
    Dtsch. Gesundh.wesen 35 (1980) 1821-1824
  3. Julius, U.; Leonhardt, W.; Schulze, J.; Hanefeld, M.; Haller, H.;
    Intravenöser Fettoleranztest mit Lipofundin S bei Normo- und Hypertriglyceridämie
    Dtsch. Gesundh.wesen 36 (1981) 580-583
  4. Julius, U.; Leonhardt, W.; Schulze, J.; Schollberg, K.; Hanefeld, M.; Haller, H.;
    Hyperinsulinemia in patients with low fractional catabolic rate of triglycerides
    Acta diabetologica latina XVIII (1981) 217-223
  5. Hanefeld, M.; Hora, C.; Laube, U.; Schulze, J.; Haller, H.; Julius, U.;
    Kurz- und Langzeitergebnisse stationärer Fastenkuren
    Dtsch. Gesundh.wesen 37 (1982) 355
  6. Haller, H.; Schulze, J.; Leonhardt, W.; Julius, U.; Hanefeld, M.; Eichhorn, D.; Noack, D.; Jaroß, W.;
    Untersuchungen zur Differentialtherapie mit lipidsenkenden Pharmaka entspr. der Triglyceridkinetik bei Patienten mit Hypertriglyceridämie
    Dt. Gesundh.wesen 19 (1984) 1409-1412
  7. Hanefeld, M.; Schulze, J.; Fischer, S.; Julius, U.; Dude, K.; Schmechel, H.; Klein, S.; Köhler, K.; Thiele, P.; Vater, H.-G.; Rothe, G.; Haller, H.;
    The Diabetes Intervention Study (DIS): a multiintervention trial in type II diabetics
    Atherosclerosis Press Lancester, Engl. 1984, 83-91
  8. Julius, U.; Leonhardt, W.;
    Elimination and metabolism of a fat emulsion containing medium chain triglycerides (Lipofundin MCT 10 %)
    Journal of Parenteral and Enteral Nutrition 12 (1988) 116-120
  9. Leonhardt, W.; Julius, U.; Schulze, J.; Hanefeld, M.; Haller, H.;
    Elimination of Lipofundin S during the intravenous fat tolerance test in patients with low, medium and high fasting triglyceride concentrations
    J. of Parenteral and Enteral Nutrition 9 (1985) 461-465
  10. Leonhardt, W.; Julius, U.;
    Elimination Kinetics of Lipofundin MCT: Bolus Injection and Infusion Compared
    Journ. of Parenteral and Enteral Nutrition 11 (1987) 57-59
  11. Julius, U.; Leonhardt, W.; Noack, D.; Schulze, J.; Nikulcheva, N.G.; Jaroß, W.; Hanefeld, M.;
    Pathogenetic role of adipose tissue lipase deficit for development of hypertriglyceridemia
    Exper. Clin. Endocrin. 94 (1989) 187-193
  12. Hanefeld, M.; Fischer, S.; Schmechel, H.; Rothe, G.; Schulze, J.; Dude, H.; Schwanebeck, U.; Julius, U.;
    Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDM
    Diabetes Care 14 (1991) 308-317
  13. Julius, U.; Fritsch, H.; Fritsch, W.; Rehak, E.; Fücker, K.; Leonhardt, W.; Hanefeld, M.;
    Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women
    The Clinical Investigator 72 (1994) 502-507
  14. Pietzsch, J.; Wiedemann, B.; Julius, U.; Nitzsche, S.; Gehrisch, S.; Bergmann, S.; Leonhardt, W.; Jaross, W.; Hanefeld, M.;
    Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach
    J Lipid Res 37 (1996) 2074-2087
  15. Hanefeld, M.; Fischer, S.; Julius, U.; Schulze, J.; Schwanebeck, U.; Schmechel, H.; Ziegelasch, H.J.; Lindner, J.; The DIS Group
    Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up
    Diabetologia 39 (1996) 1577-1583
  16. Julius, U.; Patzak, A.; Schaich, M.; Ehninger, G.; Kamin, G.;
    Immunogene Thrombozytopenie, Anämie und Leukopenie während Schwangerschaft - Erfolgreiche Extrakorporaltherapie mit Immunadsorption
    Dtsch. med. Wschr. 122 (1997) 220-224
  17. Kostka, H.; Gehrisch, S.; Freidt, M.; Hoche, I.; Julius, U.; Hanefeld, M.; Kuhlisch, E.; Jaross, W.;
    Point mutations in the lipoprotein lipase gene are likely susceptibility alleles for familial combined hyperlipidemia (FCHL)
    Clin Lab 43 (1997) 893-897
  18. Pietzsch, J.; Julius, U.; Nitzsche, S.; Hanefeld, M.
    In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47 (1998) 1928-1934
  19. Pietzsch, J.; Julius, U.; Hanefeld, M.< 1999< Metabolic basis of low high density lipoprotein in subjects with impaired glucose tolerance.< Ann. NY Acad. Sci. 892 (1999) 323-326
  20. Pietzsch, J.; Lattke, P.; Julius, U.
    Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time – in vivo insights from stable-isotope studies
    Arterioscler Thromb Vasc Biol 20 (2000) e63-e67
  21. Julius, U.; Siegert, G.; Gromeier, S.
    Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system.
    Int J Artificial Organs 23 (2000) 199-206
  22. Kopprasch, S.; Julius, U.; Gromeier, S.; Kühne, H.; Grässler, J.
    Distinct effects of LDL apheresis by hemoperfusion (DALI) and heparin-induced extracorporeal precipitation (HELP) on leukocyte respiratory burst activity of patients with familial hypercholesterolemia
    J Clin Apheresis 15 (2000) 249-255
  23. Richter, V.; Rassoul, F.; Reuter, W.; Purcz, T.; Julius, U.; Gläser, V.; Hentschel, B.; Wagner, O.
    Effect of extracorporeal low-density lipoprotein elimination on circulating cell adhesion molecules in patients with hypercholesterolemia
    Amer J Cardiology 87 (2001) 1111-1113
  24. Koch, R.; Julius, U.; Jaross, W.; Schröder, H.-E.
    Estimation of the heritability of latent variables which are included in a structural model for metabolic syndrome
    Human Heredity 52 (2001) 171-176
  25. Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 25 (2002) 1180-1188
  26. Kopprasch, S.; Pietzsch, J.; Kuhlisch, E.; Fuecker, K.; Temelkova-Kurktchiev, T.; Hanefeld, M.; Kühne, H.; Julius, U.; Graessler, J.
    In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance
    Diabetes 51 (2002) 3102-3106
  27. Metzler, W.; Fücker, K.; Schwanebeck, U.; Hanefeld, M.; Julius, U.; Kindel, B.; Fischer, S.
    Bedeutung der Triglyzeride für weitere metabolische Parameter bei familiärem metabolischem Syndrom
    Dtsch Med Wochenschr 128 (2003) 1941-1946
  28. Obrosova, I. G.; Julius, U. A.
    Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy
    Curr Vasc Pharmacology 3 (2005) 267-283
  29. Julius, U.; Jauhiainen, M.; Ehnholm, C.; Pietzsch, J.: Lipid transfer proteins in subjects with impaired glucose tolerance. Clin Chem Lab Med 45 (2007) 237-43
  30. Julius, U.; Parhofer, K. G.; Heibges, A.; Kurz, S.; Klingel, R.; Geiss, H. C.: Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis-Comparison of performance characteristics with DALI and lipidfiltration.
    J Clin Apher 22 (2007) 215-23
  31. Julius, U.; Dittrich, M.; Pietzsch, J.: Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance. Int J Clin Pract 61 (2007) 1798-804
  32. Graessler, J.; Pietzsch, J.; Westendorf, T.; Julius, U.; Bornstein, S. R.; Kopprasch, S.: Glycoxidised LDL isolated from subjects with impaired glucose tolerance increases CD36 and peroxisome proliferator-activator receptor gamma gene expression in macrophages.
    Diabetologia 50 (2007) 1080-8
  33. Rothe, U.; Müller, G.; Schwarz, P. E. H.; Seifert, M.; Kunath, H.; Koch, R.; Bergmann, S.; Julius, U.; Bornstein, S. R.; Hanefeld, M.; Schulze, J.: Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a federal state of Germany. Diabetes Care 31 (2008) 863-8
  34. Drel, V.; Pacher, P.; Ali, T. K.; Shin, J.; Julius, U.; El-Remessy, A. B.; Obrosova, I. G.: Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int J Mol Med 21 (2008) 667-76
  35. Kopprasch, S.; Graessler, J.; Bornstein, S. R.; Schwarz, P. E. H.; Tselmin, S.; Frind, A.; Poberschin, I.; Julius, U.: Beyond lowering circulating LDL: Apheresis-induced changes of  systemic oxidative stress markers by four different techniques. Atherosclerosis Supplements 10 (2009) 34 – 38
  36. Beyer-Westendorf, J.; Seitz, W.; Jabs, N.; Bramlage, P.; Kuhlisch, E.; Julius, U.; Bornstein, S. R.; Schellong, S. M.: Nitric oxide and endothelin after lipid apheresis – a pilot study. Atherosclerosis 10 (2009) 70 – 73
  37. Reimann, M.; Prieur, S.; Lippold, B.; Bornstein, S. R.; Reichmann, H.; Julius, U.; Ziemssen, T.: Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. Atherosclerosis Supplements 10 (2009) 39 – 43
  38. Tselmin, S.; Schmitz, G.; Julius, U.; Bornstein, S. R.; Barthel, A.; Graessler, J.; Acute effects of lipid apheresis on human serum lipidome. Atherosclerosis Supplements 10 (2009) 27 – 33
  39. Tselmin, S.; Julius, U.; Müller, G.; Fischer, S.; Bornstein, S. R.: Cardiovascular events in patients with increased lipoprotein(a) – retrospective data analysis in an outpatient department of lipid disorders. Atherosclerosis Supplements 10 (2009) 79 – 84
  40. Reimann, M,; Julius, U.; Haink, K.; Lippold, B.; Tselmin, S.; Bornstein, S. R.; Reichmann, H.; Ziemssen, T.: LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. Atherosclerosis 213 (2010)212 - 17
  41. Julius, U.; Tselmin, S.; Fischer, S.; Passauer, J.; Tsourdi, E.; Bornstein, S. R.: Lipid Apheresis after Heart Transplantation – the Dresden Experience. Transplantationsmedizin 22 (2010) 355-62
  42. Terai, N.; Julius, U.; Haustein, M.; Spoerl, E.; Pillunat, L. E.: The effect of low-density lipoprotein apheresis on ocular microcirculation in patients with hypercholesterolaemia: a pilot study. Br J Opthalmol 95 (2011) 401-4
  43. Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128(24):2567-2576
  44. Kopprasch S, Bornstein SR, Schwarz PE, Bergmann S, Julius U, Graessler J. Single whole blood dextran sulfate adsorption favorably affects systemic oxidative balance in lipoprotein apheresis patients. Atheroscler Suppl 2013; 14(1):157-160.
  45. Grassler J, Kopprasch S, Passauer J, Fischer S, Schuhmann K, Bergmann S et al. Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profile. Atheroscler Suppl 2013; 14(1):151-155.
  46. Reimann M, Peitzsch M, Ziemssen T, Julius U, Eisenhofer G. Metabolomic distinction of microvascular effects of lipoprotein apheresis--a pilot study. Atheroscler Suppl 2013; 14(1):143-149.
  47. Reimann M, Julius U, Bornstein SR, Fischer S, Reichmann H, Rudiger H et al. Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease. Atheroscler Suppl 2013; 14(1):135-141.
  48. Lamounier-Zepter V, Look C, Ehrhart-Bornstein M, Bornstein SR, Fischer S, Julius U. Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels. Atheroscler Suppl 2013; 14(1):129-134.
  49. Tselmin S, Rodionov RN, Muller G, Bornstein S, Julius U. Homocysteine in lipoprotein apheresis patients--retrospective data analysis in apheresis center of a university hospital. Atheroscler Suppl 2013; 14(1):123-128.
  50. Schatz U, Arneth B, Siegert G, Siegels D, Fischer S, Julius U et al. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations. Atheroscler Suppl 2013; 14(1):115-122.
  51. Morawietz H, Goettsch W, Brux M, Reimann M, Bornstein SR, Julius U et al. Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. Atheroscler Suppl 2013; 14(1):107-113.
  52. Taseva K, Fischer S, Passauer J, Weiss N, Bornstein SR, Julius U. Factors inducing cardiovascular events in patients treated by lipoprotein apheresis. Atheroscler Suppl 2013; 14(1):45-50.
  53. von Dryander, M, Fischer S, Passauer J, Muller G, Bornstein SR, Julius U. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 2013; 14(1):39-44.
  54. Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl 2013; 14(1):19-27.
  55. Fischer S, Schatz U, Julius U. Current standards in diagnosis and therapy of hyperlipoproteinemia. Atheroscler Suppl 2013; 14(1):15-18
  56. Julius U, Fischer S, Schatz U, Passauer J, Bornstein S. Why an apheresis center should offer more than one lipoprotein apheresis method. Ther Apher Dial 2013; 17(2):179-184
  57. Julius U, Taseva K, Fischer S, Passauer J, Bornstein SR. Current situation of lipoprotein apheresis in Saxony. Atheroscler Suppl 2013; 14(1):51-55
  58. Julius U, Fischer S. Nicotinic acid as a lipid-modifying drug--a review. Atheroscler Suppl 2013; 14(1):7-13
  59. Julius U. Niacin as antidyslipidemic drug. Can J Physiol Pharmacol 2015;93(12):1043-1054
  60. Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, et al. Effects of lipoprotein apheresis on PCSK9 levels. Atheroscler Suppl 2015;18:180-186
  61. Julius U, Siegert G, Kostka H, Schatz U, Hohenstein B. Effects of different lipoprotein apheresis methods on serum protein levels. Atheroscler Suppl 2015;18:95-102
  62. Tselmin S, Muller G, Gelgaft E, Fischer S, Julius U. An elevated lipoprotein(a) plasma level as a cardiovascular risk factor. Atheroscler Suppl 2015;18:257-262
  63. Stefanutti C, D'Alessandri G, Petta A, Harada-Shiba M, Julius U, Soran H, et al. First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias. Atheroscler Suppl 2015;18:241-250.
  64. Stasiewski E, Christoph M, Christoph A, Bittner A, Weidner K, Julius U. Mental symptoms and quality of life in lipoprotein apheresis patients in comparison to hemodialysis patients, platelet donors and normal population. Atheroscler Suppl 2015;18:233-240.
  65. Gross E, Hohenstein B, Julius U. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run. Atheroscler Suppl 2015;18:226-232.
  66. Emmrich U, Hohenstein B, Julius U. Actual situation of lipoprotein apheresis in Saxony in 2013. Atheroscler Suppl 2015;18:215-225.
  67. Schampera S, Fischer S, Weiss N, Julius U. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment. Atheroscler Suppl 2015;18:209-214.
  68. Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, et al. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Atheroscler Suppl 2015;18:199-208.
  69. Fischer S, Schatz U, Julius U. Practical recommendations for the management of hyperlipidemia. Atheroscler Suppl 2015;18:194-198.
  70. Graessler J, Schuhmann K, Shevchenko A, Kopprasch S, Ban R, Bergmann S, et al. Increasing plasma lysophosphatidylcholine levels in patients with regular dextran sulfate lipoprotein apheresis. Atheroscler Suppl 2015;18:170-175.
  71. Scholz M, Tselmin S, Fischer S, Julius U. Hypertriglyceridemia in an outpatient department--Significance as an atherosclerotic risk factor. Atheroscler Suppl 2015;18:146-153.
  72. Hohenstein B, Passauer J, Ziemssen T, Julius U. Immunoadsorption with regenerating systems in neurological disorders --A single center experience. Atheroscler Suppl 2015;18:119-123.
  73. Stefanutti C, Julius U. Treatment of primary hypertriglyceridemia states--General approach and the role of extracorporeal methods. Atheroscler Suppl 2015;18:85-94.
  74. Kopprasch S, Bornstein SR, Bergmann S, Graessler J, Julius U. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters--A comparison of two different apheresis techniques. Atheroscler Suppl 2015;18:80-84.
  75. Dittrich-Riediger J, Schatz U, Hohenstein B, Julius U. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden. Atheroscler Suppl 2015;18:45-52.
  76. Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, et al. First data from the German Lipoprotein Apheresis Registry (GLAR). Atheroscler Suppl 2015;18:41-44.
  77. Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, et al. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels. Clin Res Cardiol Suppl 2015;10:14-20
  78. Julius U. Statine und erhöhte Inzidenz an Diabetes. Diabetes aktuell 2015;13:208-214
  79. Schettler VJ, Roeseler E, Thode C, Grützmacher P, Klingel R, Julius U. Differenzierung der Indikation zur Lipoproteinapherese bei erhöhtem Lp(a) durch unterschiedliche Messmethoden. CARDIOVASC 2015; 15:36-38
  80. Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R, ProLiFe-Study G. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol 2016;36:2019-27.
  81. Rodrigues R, Artieda M, Tejedor D, Martinez A, Konstantinova P, Petry H, Meyer C, Corzo D, Sundgreen C, Klor HU, Gouni-Berthold I, Westphal S, Steinhagen-Thiessen E, Julius U, Winkler K, Stroes E, Vogt A, Hardt P, Prophet H, Otte B, Nordestgaard BG, Deeb SS, Brunzell JD. Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency. J Clin Lipidol 2016;10:394-409
  82. Julius U. Wirkungsweise und Effekte der PCSK9-Inhibitoren. herzmedizin 2016:22-7
  83. Julius U. Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection. Med Devices (Auckl) 2016;9:349-60.
  84. Schettler V, Hohenstein B, Julius U, Klingel R. Therapeutische Apherese - Wie ist der aktuelle Stand? Dialyse aktuell 2016;20:490 - 6
  85. Julius U. History of lipidology and lipoprotein apheresis. Atheroscler Suppl 2017;30:1-8.
  86. Tselmin S, Muller G, Schatz U, Julius U, Bornstein SR, Hohenstein B. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia. Atheroscler Suppl 2017;30:209-16
  87. Tselmin S, Julius U, Bornstein SR, Hohenstein B. Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins. Atheroscler Suppl 2017;30:278-82
  88. Sradnick J, Tselmin S, Wagner A, Julius U, Todorov V, Hugo C, Hohenstein B. H.E.L.P apheresis exerts long term effects on the capacity of circulating proangiogenic cells. Atheroscler Suppl 2017;30:232-7.
  89. Schmidt N, Grammer T, Gouni-Berthold I, Julius U, Kassner U, Klose G, Konig C, Laufs U, Otte B, Steinhagen-Thiessen E, Wanner C, Marz W. CaRe high - Cascade screening and registry for high cholesterol in Germany. Atheroscler Suppl 2017;30:72-6.
  90. Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grutzmacher P, German Society of Nephrology, the Foundation of German Centers of Nephrology. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both? Atheroscler Suppl 2017;30:44-9.
  91. Schatz U, Tselmin S, Muller G, Julius U, Hohenstein B, Fischer S, Bornstein SR. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study. Atheroscler Suppl 2017;30:246-52
  92. Korneva V, Kuznetsova T, Julius U. Analysis of lipid metabolism and its impact on the risk of ischemic heart disease in patients with definite familial hypercholesterolemia. Atheroscler Suppl 2017;30:56-62.
  93. Kopprasch S, Bornstein SR, Bergmann S, Graessler J, Hohenstein B, Julius U. Long-term follow-up of circulating oxidative stress markers in patients undergoing lipoprotein apheresis by Direct Adsorption of Lipids (DALI). Atheroscler Suppl 2017;30:115-21.
  94. Jellinghaus S, Reich C, Schatz U, Tselmin S, Ibrahim K, Pfluecke C, Schauer A, Bornstein SR, Hohenstein B, Strasser RH, Julius U, Poitz DM. Lipoprotein apheresis influences monocyte subpopulations. Atheroscler Suppl 2017;30:108-14.
  95. Hohenstein B, Tselmin S, Bornstein SR, Julius U. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center. Atheroscler Suppl 2017;30:28-32.
  96. Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes. Atheroscler Suppl 2017;30:180-6
  97. Heigl F, Pflederer T, Schettler V, Grutzmacher P, Julius U, Ringel J, David-Walek T, Hettich R, Lotz N, Reeg H, Graf M, Klor HU. Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolism. Atheroscler Suppl 2017;30:63-71.
  98. Fischer S, Julius U. Management of patients with statin intolerance. Atheroscler Suppl 2017;30:33-7.
  99. Dietze J, Hohenstein B, Tselmin S, Julius U, Bornstein SR, Beissert S, Gunther C. Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris. Atheroscler Suppl 2017;30:271-7
  100. Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grutzmacher P, Blume H, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on. Clin Res Cardiol Suppl 2017;12:44-9
  101. Kroemer TM, Erler A, Tsourdi E, Gruber M, Tselmin S, Julius U, Aringer M, Hofbauer LC, Rachner TD. Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report. Diabetes Care 2018;41:e23-e24
  102. Schmidt N, Dressel A, Grammer TB, Gouni-Berthold I, Julius U, Kassner U, Klose G, Konig C, Koenig W, Otte B, Parhofer KG, Reinhard W, Schatz U, Schunkert H, Steinhagen-Thiessen E, Vogt A, Laufs U, Marz W. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. Atherosclerosis 2018;277:314-22
  103. De Gucht V, Cromm K, Vogt A, Julius U, Hohenstein B, Spitthover RM, Ramlow W, Schettler VJJ, Maes S. Treatment-related and health-related quality of life in lipoprotein apheresis patients. J Clin Lipidol 2018;5:1225-1233
  104. Julius U, Tselmin S, Bornstein SR. Lipoprotein apheresis: yesterday, today, tomorrow. Russ J Cardiol 2018;23:74-8
  105. Weiss N, Julius U. Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results. Clin Res Cardiol Suppl 2019;14:39-44
  106. Julius U, Tselmin S, Schatz U, Fischer S, Bornstein SR. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clin Res Cardiol Suppl 2019;14:45-50.
  107. Julius U, Tselmin S, Schatz U, Fischer S, Bornstein SR. Lipoprotein(a)-an interdisciplinary challenge. Clin Res Cardiol Suppl 2019;14:20-7.
  108. Julius U, Tselmin S, Schatz U, Fischer S, Bornstein SR. Indikation und Ergebnisse der Apherese-Behandlung bei Lipoprotein(a)- Erhöhungen. CardioVasc 2019;19:35-39.
  109. Julius U, Tselmin S, Schatz U, Fischer S, Birkenfeld AL, Bornstein SR. Actual situation of  Lipoprotein apheresis in patients with elevated Lipoprotein(a) levels. Atheroscler Suppl 2019;40:1-7
  110. Walther R, Julius U, Tselmin S, Schatz U, Bornstein SR, Graessler J. Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia. Atheroscler Suppl 2019;40:30-7.
  111. Tselmin S, Julius U, Weinert N, Bornstein SR, Schatz U. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis. Atheroscler Suppl 2019;40:38-43.
  112. Straube R, Muller G, Voit-Bak K, Tselmin S, Julius U, Schatz U, Rietzsch H, Reichmann H, Chrousos GP, Schurmann A, Jarc L, Ziemssen T, Siepmann T, Bornstein SR. Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis? Horm Metab Res 2019;51:779-84.
  113. Spitthover R, Roseler T, Julius U, Heigl F, Schettler VJJ, Kuhn R, Leebmann J, Raabe A, Knittel M, Schurfeld C, Moesenthin M, Bernhardt WM, Roseler E, Ketteler M, Heibges A, Klingel R. Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. J Clin Apher 2019:1-11.
  114. Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Hohenstein B, Roeseler E, Heigl F, Grutzmacher P, Blume H, Klingel R, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Clin Res Cardiol Suppl 2019;14:33-8.
  115. Julius U. Herkömmliche und zukünftige Therapiekonzepte bei Hypertriglyzeridämie. Nieren- und Hochdruckkrankheiten 2019;48:391-9
  116. Schettler V, de Groot K, Fassbender C, Grützmacher P, Heigl F, Julius U, Kielstein J, Klaus G, Klingel R, Roeseler E, Schmitt C-P, Taylan C, Thumfart J, Vogt A, Weiss N, Hohenstein B. Standard der Therapeutischen Apherese 2019
  117. Schatz U, Fischer S, Muller G, Tselmin S, Birkenfeld AL, Julius U, Marz W, Bornstein SR. Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic. Atheroscler Suppl 2019;40:94-9
  118. Korneva V, Kuznetsova T, Julius U. Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia. Atheroscler Suppl 2019;40:79-87.
  119. Klingel R, Heigl F, Schettler V, Roeseler E, Grutzmacher P, Hohenstein B, Vogt A, Fassbender C, Heibges A, Julius U. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis. Atheroscler Suppl 2019;40:17-22.
  120. Heigl F, Pflederer T, Klingel R, Hettich R, Lotz N, Reeg H, Schettler VJJ, Roeseler E, Grutzmacher P, Hohenstein B, Julius U. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy? Atheroscler Suppl 2019;40:23-9
  121. Fischer S, Schatz U, Julius U, Tselmin S, Bornstein S. Bedeutung der Lp(a)-Spiegel: zwei Kasuistiken - Patienten mit Hypercholesterinämie, massiv erhöhtem Lipoprotein(a)-Spiegel und schweren Gefäßkomplikationen. Ärzteblatt Sachsen 2019:23 - 6
  122. Julius U, Tselmin S, Schatz U, Fischer S, Bornstein SR. Aktuelle Rolle der PCSK9-Inhibitoren bei der Behandlung von Hypercholesterinämie-Patienten. Herzmedizin 2020;1:19-27.
  123. Julius U, Kuss S, Tselmin S, Schatz U, Bornstein SR. Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events? J Cardiovasc Dev Dis 2020;7.
  124. Julius U. Einfluss erhöhter Lipoproteinkonzentrationen auf die Prognose von Patienten mit Diabetes mellitus. Diabetes aktuell 2020;18:234-40
  125. Morawietz H, Julius U, Bornstein SR. Cardiovascular diseases, lipid-lowering therapies and European registries in the COVID-19 pandemic. Cardiovasc Res 2020;116:e122-e5.
  126. Bornstein SR, Voit-Bak K, Schmidt D, Morawietz H, Bornstein AB, Balanzew W, Julius U, Rodionov RN, Biener AM, Wang J, Schulte KM, Krebs P, Vollmer G, Straube R. Is There a Role for Environmental and Metabolic Factors Predisposing to Severe COVID-19? Horm Metab Res 2020;52:540-6.
  127. Bornstein SR, Voit-Bak K, Rosenthal P, Tselmin S, Julius U, Schatz U, Boehm BO, Thuret S, Kempermann G, Reichmann H, Chrousos GP, Licinio J, Wong ML, Schally AV, Straube R. Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammation. Mol Psychiatry 2020;25:275-82